| __timestamp | Viking Therapeutics, Inc. | Xencor, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 1244910 | 7461000 |
| Thursday, January 1, 2015 | 5029636 | 11960000 |
| Friday, January 1, 2016 | 4846776 | 13108000 |
| Sunday, January 1, 2017 | 5329003 | 17501000 |
| Monday, January 1, 2018 | 7121000 | 22472000 |
| Tuesday, January 1, 2019 | 9128000 | 24286000 |
| Wednesday, January 1, 2020 | 10731000 | 29689000 |
| Friday, January 1, 2021 | 10701000 | 38837000 |
| Saturday, January 1, 2022 | 16121000 | 47489000 |
| Sunday, January 1, 2023 | 37021000 | 53379000 |
Unleashing insights
In the competitive landscape of biotechnology, operational efficiency is key. Over the past decade, Viking Therapeutics, Inc. and Xencor, Inc. have showcased contrasting strategies in managing their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Xencor consistently outpaced Viking in SG&A spending, peaking at $53 million in 2023, a 600% increase from 2014. Viking, however, demonstrated a more conservative approach, with a notable surge in 2023, reaching $37 million, marking a 2,900% increase from its 2014 figures. This divergence highlights Xencor's aggressive investment in operational activities, while Viking's recent spike suggests a strategic pivot. As these companies navigate the biotech sector's challenges, their SG&A trends offer insights into their evolving business models and market positioning.
Who Optimizes SG&A Costs Better? Sanofi or Viking Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Gilead Sciences, Inc. and Viking Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Biogen Inc. and Xencor, Inc.
Genmab A/S vs Xencor, Inc.: SG&A Expense Trends
Incyte Corporation and Viking Therapeutics, Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: BioMarin Pharmaceutical Inc. vs Xencor, Inc. Trends and Insights
Who Optimizes SG&A Costs Better? Pharming Group N.V. or Xencor, Inc.
Who Optimizes SG&A Costs Better? Apellis Pharmaceuticals, Inc. or Viking Therapeutics, Inc.
Viking Therapeutics, Inc. and Evotec SE: SG&A Spending Patterns Compared
Selling, General, and Administrative Costs: Soleno Therapeutics, Inc. vs Xencor, Inc.
Amphastar Pharmaceuticals, Inc. and Xencor, Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Celldex Therapeutics, Inc. vs Xencor, Inc. Trends and Insights